Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for bisphosphonate-refractory hypercalcemia of malignancy
2009-009756-21Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in cancer-associated hypercalcemia, sponsored by Amgen. Primary endpoint: Response within 10 days. Started Sep 2009; status: completed.
02
Drugs
denosumab
03
Conditions
cancer-associated hypercalcemia
Beyond the preview
Go deeper on 2009-009756-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009756-21.